Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Health Care's 5 Worst November Flops
Motley Fool
Thursday, December 1, 2011 - 11:42am
tags:
Vertex, Seattle Genetics, Human Genome Sciences, Mako Surgical, Dendreon
Senators Probe Pfizer Plan To Block Generic Lipitor
Pharmalot
Thursday, December 1, 2011 - 11:28am
tags:
Senate, Pfizer, generics, Lipitor, PBMs
Mylan Sued by Warner Chilcott for Patent Infringement Over Generess FE
Bloomberg
Thursday, December 1, 2011 - 11:27am
tags:
Mylan, Warner Chilcott, patents, Generess FE, birth control pill
Drugmaker Pfizer completes acquisition of Ferrosan Consumer Health business
Yahoo/AP
Thursday, December 1, 2011 - 11:25am
tags:
Ferrosan, Pfizer, M&A, Europe
Pfizer Out Of Lipitor's Shadow, But Still Expects To Grow Profits
Seeking Alpha
Thursday, December 1, 2011 - 11:24am
tags:
Lipitor, generics, Pfizer
Takeda May Face 10,000 U.S. Suits Over Actos Cancer Claims
Bloomberg
Thursday, December 1, 2011 - 10:40am
tags:
Takeda, Actos, lawsuits, diabetes, bladder cancer
Ranbaxy launches Lipitor generic in U.S., shares surge
Yahoo/Reuters
Thursday, December 1, 2011 - 10:39am
tags:
Lipitor, generics, statins, Pfizer, Ranbaxy
Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency
Bloomberg
Wednesday, November 30, 2011 - 7:42pm
tags:
Novartis, MS, multiple sclerosis, Gilenya
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
Seeking Alpha
Wednesday, November 30, 2011 - 5:29pm
tags:
Krystexxa, Savient, gout
A Simple Plan (to Save US Pharma Manufacturing)
Pharm Exec
Wednesday, November 30, 2011 - 2:19pm
tags:
drug manufacturing
Hospira's production woes widespread, analyst says
Fierce Pharma
Wednesday, November 30, 2011 - 2:13pm
tags:
Hospira, drug manufacturing
Pfizer and Merck May Benefit From Spinoffs, Goldman Sachs Says
Bloomberg
Wednesday, November 30, 2011 - 2:10pm
tags:
Pfizer, Merck, spinoff
Two Top Biotech Plays With Safe Upside
Seeking Alpha
Wednesday, November 30, 2011 - 2:09pm
tags:
ImmunoCellular, glioblastoma multiforme, brain cancer, Bristol-Myers Squibb, Yervoy, melanoma
Why the Street Should Love Merck's Earnings
Motley Fool
Wednesday, November 30, 2011 - 11:51am
tags:
Merck, earnings
Rivals threaten to take wind from Watson’s generic Lipitor sales
Med City
Wednesday, November 30, 2011 - 11:31am
tags:
Watson, generics, Pfizer, Lipitor, Teva Pharmaceuticals, Ranbaxy
Pfizer After Lipitor to Push Mini-Blockbusters
Bloomberg
Wednesday, November 30, 2011 - 11:29am
tags:
Pfizer, generics, Lipitor
Why There Will Never Be Another Drug Like Lipitor
Forbes
Wednesday, November 30, 2011 - 11:28am
tags:
Pfizer, generics, statins, Lipitor
GSK shakes up R&D units during high-profile review
Fierce Biotech
Wednesday, November 30, 2011 - 10:50am
tags:
GSK, R&D
New Drug Approvals Make Or Break Biotechnology Stocks
Seeking Alpha
Wednesday, November 30, 2011 - 10:46am
tags:
Antares, Achillion, Pharmasset, Indenix, Inhibitex, ONYX Pharmaceuticals, Keryx
Every Biotech Is for Sale
Motley Fool
Wednesday, November 30, 2011 - 10:45am
tags:
ONYX Pharmaceuticals, Achillion, BioSante, Indenix, Inhibitex, GSK, Bristol-Myers Squibb, Amarin, Exelixis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.